National Generic Consent Form from CRUK

National Systemic Anti-Cancer Therapy (SACT) consent forms – for Generic SACT form

The consent form project team is pleased to announce that the national generic consent form has been reviewed and published on the Cancer Research UK website.

Please visit www.cruk.org/sact_consent to view and download the forms.  Other forms, national guidance on consent for SACT, and further information is also available via the website.

Please do not hesitate to contact Alia Nizam (Oncology Pharmacist – CRUK information lead, Guy’s and St. Thomas’ NHS Foundation Trust) if you have any queries: [email protected]

Alia Nizam
21st  Jan 2020

Latest News

By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article
By BOPA IO SAG on 23rd April 2025

Toolkit for Immunotherapy IV to SC switch

Dear all, In the coming months, an increasing number of products traditionally administered intravenously are expected to become available for subcutaneous administration. This shift offers enhanced flexibility for patients; however,…

Read article
By BOPA E&T subcommittee on 17th April 2025

The BOPA Cancer Consultant Pharmacist Credentialing Support Series is back

BOPA are holding a nine month supportive webinar series for pharmacists who are credentialing as consultant pharmacists with the RPS. Join in this relaxed forum to discuss about your portfolio…

Read article
By BOPA research subcommittee on 17th April 2025

Celebration of BOPA member’s recent publications

We are delighted to share that so many of our members have had manuscripts published recently. Here are some that we are aware of but if there are others then…

Read article